JP2018508229A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018508229A5 JP2018508229A5 JP2017557264A JP2017557264A JP2018508229A5 JP 2018508229 A5 JP2018508229 A5 JP 2018508229A5 JP 2017557264 A JP2017557264 A JP 2017557264A JP 2017557264 A JP2017557264 A JP 2017557264A JP 2018508229 A5 JP2018508229 A5 JP 2018508229A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- seq
- amino acid
- acid sequence
- single domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 40
- 125000003275 alpha amino acid group Chemical group 0.000 claims 17
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 16
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 239000002773 nucleotide Substances 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- 230000004913 activation Effects 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 210000000581 natural killer T-cell Anatomy 0.000 claims 2
- VQFKFAKEUMHBLV-BYSUZVQFSA-N 1-O-(alpha-D-galactosyl)-N-hexacosanoylphytosphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)[C@H](O)CCCCCCCCCCCCCC)CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQFKFAKEUMHBLV-BYSUZVQFSA-N 0.000 claims 1
- 229930186217 Glycolipid Natural products 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 238000002405 diagnostic procedure Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2014192 | 2015-01-27 | ||
| NL2014192 | 2015-01-27 | ||
| PCT/NL2016/050064 WO2016122320A1 (en) | 2015-01-27 | 2016-01-27 | Single domain antibodies targeting cd1d |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020127379A Division JP7165701B2 (ja) | 2015-01-27 | 2020-07-28 | Ｃｄ１ｄを標的とする単一ドメイン抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018508229A JP2018508229A (ja) | 2018-03-29 |
| JP2018508229A5 true JP2018508229A5 (cg-RX-API-DMAC10.html) | 2019-03-07 |
| JP6743051B2 JP6743051B2 (ja) | 2020-08-19 |
Family
ID=52630466
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017557264A Active JP6743051B2 (ja) | 2015-01-27 | 2016-01-27 | Ｃｄ１ｄを標的とする単一ドメイン抗体 |
| JP2020127379A Active JP7165701B2 (ja) | 2015-01-27 | 2020-07-28 | Ｃｄ１ｄを標的とする単一ドメイン抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020127379A Active JP7165701B2 (ja) | 2015-01-27 | 2020-07-28 | Ｃｄ１ｄを標的とする単一ドメイン抗体 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US10501541B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3250608B1 (cg-RX-API-DMAC10.html) |
| JP (2) | JP6743051B2 (cg-RX-API-DMAC10.html) |
| KR (2) | KR20230132604A (cg-RX-API-DMAC10.html) |
| CN (2) | CN107531787B (cg-RX-API-DMAC10.html) |
| AU (2) | AU2016212777B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2975078A1 (cg-RX-API-DMAC10.html) |
| EA (1) | EA201791691A1 (cg-RX-API-DMAC10.html) |
| MX (1) | MX386714B (cg-RX-API-DMAC10.html) |
| SG (1) | SG11201706128PA (cg-RX-API-DMAC10.html) |
| WO (1) | WO2016122320A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX386714B (es) | 2015-01-27 | 2025-03-11 | Lava Therapeutics N V | Anticuerpos de dominio simple dirigidos al grupo de diferenciación 1d (cd1d). |
| JP7457007B2 (ja) * | 2018-09-19 | 2024-03-27 | ラヴァ・セラピューティクス・エヌ・ヴイ | 二重作用ＣＤ１ｄ免疫グロブリン |
| WO2020113063A1 (en) | 2018-11-30 | 2020-06-04 | Aleta Biotherapeutics Inc. | Single domain antibodies against cll-1 |
| EP3792283A1 (en) | 2019-09-16 | 2021-03-17 | Lava Therapeutics B.V. | Treatment of cancer comprising administration of vgamma9vdelta2 t cell receptor binding antibodies |
| EP4301374A4 (en) | 2021-03-01 | 2025-09-10 | Deciduous Therapeutics Inc | COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLS |
| JP2024538958A (ja) | 2021-10-21 | 2024-10-28 | ラヴァ・セラピューティクス・エヌ・ヴイ | ガンマデルタｔ細胞活性化抗体の使用 |
| CN116239687B (zh) * | 2021-12-22 | 2026-03-24 | 北京世纪沃德生物科技有限公司 | 一种crp驼源单域抗体及其制备方法和应用 |
| EP4285926A1 (en) * | 2022-05-30 | 2023-12-06 | LAVA Therapeutics N.V. | Combination treatment for chronic lymphocytic leukemia |
| EP4292610A1 (en) | 2022-06-15 | 2023-12-20 | LAVA Therapeutics N.V. | Variant antibodies that bind gamma-delta t cell receptors |
| WO2024256586A1 (en) | 2023-06-14 | 2024-12-19 | LAVA Therapeutics N.V. | Cd1d antibodies and methods of use |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2698880B1 (fr) | 1992-11-25 | 1995-02-24 | Inst Nat Sante Rech Med | Procédé de production de récepteurs T solubles, produits ainsi obtenus et leur utilisation dans des compositions diagnostiques ou thérapeutiques. |
| DK0751780T3 (da) | 1993-06-21 | 2003-10-13 | Brigham & Womens Hospital | Fremgangsmåder til isolering af CD1-fremviste antigener, vacciner, som omfatter CD1-fremviste antigener, og cellelinier til anvendelse i nævnte fremgangsmåder |
| NZ513356A (en) | 1999-02-05 | 2004-01-30 | Univ Leiden | Method of modulating metabolite biosynthesis in recombinant cells using an AP2-domain transcription factor that is involved in the response of a plant cell to a jasmonate |
| WO2001009300A2 (en) | 1999-08-02 | 2001-02-08 | Keygene N.V. | Method for generating cgmmv resistant plants, genetic constructs, and obtained cgmmv-resistant plants |
| US6737398B1 (en) | 1999-09-30 | 2004-05-18 | National Jewish Medical And Research Center | Modulation of γδ T cells to regulate airway hyperresponsiveness |
| WO2001022816A1 (en) | 1999-09-30 | 2001-04-05 | National Jewish Medical And Research Center | MODULATION OF ηδ T CELLS TO REGULATE AIRWAY HYPERRESPONSIVENESS |
| WO2001082960A1 (en) | 2000-04-28 | 2001-11-08 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of polyclonal b cell activation and immunoglobulin class switching to pathogenic autoantibodies by blocking cd1-mediated interactions |
| EP1297017B1 (en) | 2000-06-19 | 2012-06-13 | Beth Israel Deaconess Medical Center | Compositions and methods of monoclonal and polyclonal antibodies specific for t cell subpopulations |
| CA2441893C (en) | 2001-03-26 | 2015-01-20 | Dana-Farber Cancer Institute, Inc. | Method of attenuating reactions to skin irritants |
| US8178098B2 (en) | 2001-04-03 | 2012-05-15 | National Jewish Health | Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies |
| CA2476166C (en) | 2002-02-14 | 2011-11-15 | Immunomedics, Inc. | Anti-cd20 antibodies and fusion proteins thereof and methods of use |
| AU2003210060B2 (en) | 2002-03-22 | 2010-02-25 | Aprogen, Inc. | Humanized antibody and process for preparing same |
| WO2003092615A2 (en) * | 2002-05-01 | 2003-11-13 | Beth Israel Deaconess Medical Center | Use of anti-cd1 antibodies for the modulation of immune responses |
| EP1565482B1 (en) | 2002-10-23 | 2014-04-30 | Ludwig Institute for Cancer Research Ltd. | A34 and a33-like 3 dna, proteins, antibodies thereto and methods of treatment using same |
| NZ540194A (en) | 2002-11-08 | 2008-07-31 | Ablynx Nv | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| WO2005046711A2 (en) | 2003-11-07 | 2005-05-26 | Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Stimulation or inhibition of gamma delta t-cells to promote or inhibit bone healing |
| SG188175A1 (en) | 2004-06-03 | 2013-03-28 | Novimmune Sa | Anti-cd3 antibodies and methods of use thereof |
| ATE476497T1 (de) | 2004-08-19 | 2010-08-15 | Univ Cardiff | Präparation antigenpräsentierender menschlicher gamma delta t-zellen und verwendung in der immuntherapie |
| ATE539757T1 (de) | 2004-11-02 | 2012-01-15 | Univ Leland Stanford Junior | Verfahren zur hemmung von nkt-zellen |
| US8338173B2 (en) | 2005-08-11 | 2012-12-25 | University College Cardiff Consultants Limited | Preparation of antigen-presenting human γδ T cells and use in immunotherapy |
| EP2441468B1 (en) * | 2006-02-22 | 2020-01-08 | Riken | Immunotherapy by using cell capable of co-expressing target antigen and cd1d and pulsed with cd1d ligand |
| GB0605247D0 (en) * | 2006-03-15 | 2006-04-26 | Chiron Srl | Compositions and methods for immunisation |
| EP1878440A1 (en) | 2006-07-13 | 2008-01-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta cell activator compounds |
| US8012484B2 (en) | 2007-04-12 | 2011-09-06 | University Of Virginia Patent Foundation | Method of treating ischemia reperfusion injury by inhibiting NKT cell activity |
| EP2058388A1 (en) * | 2007-10-05 | 2009-05-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Non-conventional NKT cells for use in cancer therapy |
| WO2010130830A2 (en) * | 2009-05-15 | 2010-11-18 | Ablynx N.V. | Amino acid sequences directed against sclerostin and polypeptides comprising the same for the treatment of bone diseases and disorders |
| SG11201400521PA (en) * | 2011-10-14 | 2014-08-28 | Teva Pharmaceuticals Australia Pty Ltd | ANTIBODIES TO CD1d |
| WO2013110531A1 (en) | 2012-01-23 | 2013-08-01 | Ablynx Nv | Sequences directed against hepatocyte growth factor (hgf) and polypeptides comprising the same for the treatment of cancers and/or tumors |
| DK2831109T3 (en) | 2012-03-28 | 2018-02-12 | Gadeta B V | COMBINATORY GAMMA-9-DELTA-2-T-CELL RECEPTOR CHAIN EXCHANGE |
| WO2013174404A1 (en) | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2013174403A1 (en) | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2014127785A1 (en) | 2013-02-20 | 2014-08-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| US20170029454A1 (en) | 2013-06-28 | 2017-02-02 | The Scripps Research Institute | Nkt cell ligands and methods of use |
| EP3105252B1 (en) | 2014-02-12 | 2019-07-24 | Michael Uhlin | Bispecific antibodies for use in stem cell transplantation |
| US10501540B2 (en) | 2014-04-10 | 2019-12-10 | Lava Therapeutics B.V. | Immunoglobulins binding human Vγ9 Vδ2 T cell receptors |
| KR20170017916A (ko) | 2014-05-13 | 2017-02-15 | 추가이 세이야쿠 가부시키가이샤 | 면역 억제 기능을 갖는 세포에 대한 t 세포 리다이렉트 항원 결합 분자 |
| KR20170021354A (ko) | 2014-07-02 | 2017-02-27 | 인스티튜트 내셔널 드 라 싼테 에 드 라 리셰르셰 메디칼르 (인 썸) | CD1d 제한된 감마/델타 T 세포 림프종을 진단 및 치료하는 방법 |
| RU2756247C2 (ru) | 2014-11-17 | 2021-09-28 | Эдисет Био, Инк. | Генетически модифицированные гамма дельта т-клетки |
| MX386714B (es) | 2015-01-27 | 2025-03-11 | Lava Therapeutics N V | Anticuerpos de dominio simple dirigidos al grupo de diferenciación 1d (cd1d). |
| CN104829730A (zh) | 2015-04-14 | 2015-08-12 | 苏静 | 一种能联合免疫细胞增强肿瘤杀伤能力的双特异性抗体及其制备方法和应用 |
| US11000603B2 (en) | 2015-04-14 | 2021-05-11 | Benhealth Biopharmaceutic (Shenzhen) Co., Ltd. | Multi-specific binding conjugate, related pharmaceutical compositions and use |
| JP6931329B2 (ja) | 2015-11-18 | 2021-09-01 | 中外製薬株式会社 | 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法 |
| EP3450460B1 (en) | 2016-04-29 | 2023-07-12 | Benhealth Biopharmaceutic (Shenzhen) Co. Ltd. | Multi-specific binding conjugate, related pharmaceutical compositions and use |
| EP3490675A4 (en) | 2016-07-29 | 2020-07-29 | New York University | T GAMMA DELTA LYMPHOCYTES USED AS A TARGET FOR THE TREATMENT OF SOLID TUMORS |
| CA3049791A1 (en) | 2017-01-27 | 2018-08-02 | Silverback Therapeutics, Inc. | Tumor targeting conjugates and methods of use thereof |
| WO2018229163A1 (en) | 2017-06-14 | 2018-12-20 | King's College London | Methods of activating v delta 2 negative gamma delta t cells |
| TWI687227B (zh) | 2017-10-03 | 2020-03-11 | 生倍科技股份有限公司 | 用於t細胞免疫療法之組合及其用途 |
| KR20200142525A (ko) | 2018-04-05 | 2020-12-22 | 노파르티스 아게 | 암에 대한 삼중특이성 결합 분자 및 이의 용도 |
| WO2020010250A2 (en) | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| SG11202109122SA (en) | 2019-02-21 | 2021-09-29 | Marengo Therapeutics Inc | Anti-tcr antibody molecules and uses thereof |
| JP7686571B2 (ja) | 2019-05-08 | 2025-06-02 | ヤンセン バイオテツク，インコーポレーテツド | Ｔ細胞媒介性免疫を調節するための材料及び方法 |
| JP2022545196A (ja) | 2019-08-16 | 2022-10-26 | ガンマデルタ セラピューティクス リミテッド | 抗ｔｃｒデルタ可変１抗体の治療的使用 |
| CA3148588A1 (en) | 2019-08-16 | 2021-02-25 | GammaDelta Therapeutics Limited | Ex vivo gamma delta t cell populations |
| CA3173268A1 (en) | 2020-02-27 | 2021-09-02 | Janssen Biotech, Inc. | Materials and methods for modulating an immune response |
| WO2021183845A1 (en) | 2020-03-13 | 2021-09-16 | Janssen Biotech, Inc. | Materials and methods for modulating delta chain mediated immunity |
| US12076413B2 (en) | 2020-10-28 | 2024-09-03 | Janssen Biotech, Inc. | Compositions and methods for modulating delta gamma chain mediated immunity |
-
2016
- 2016-01-27 MX MX2017009680A patent/MX386714B/es unknown
- 2016-01-27 CN CN201680007612.0A patent/CN107531787B/zh not_active Withdrawn - After Issue
- 2016-01-27 KR KR1020237029643A patent/KR20230132604A/ko active Pending
- 2016-01-27 US US15/546,406 patent/US10501541B2/en active Active
- 2016-01-27 EP EP16715360.0A patent/EP3250608B1/en not_active Revoked
- 2016-01-27 JP JP2017557264A patent/JP6743051B2/ja active Active
- 2016-01-27 WO PCT/NL2016/050064 patent/WO2016122320A1/en not_active Ceased
- 2016-01-27 AU AU2016212777A patent/AU2016212777B2/en not_active Revoked
- 2016-01-27 KR KR1020177024072A patent/KR102574729B1/ko active Active
- 2016-01-27 SG SG11201706128PA patent/SG11201706128PA/en unknown
- 2016-01-27 EA EA201791691A patent/EA201791691A1/ru unknown
- 2016-01-27 CN CN202111671891.XA patent/CN114504645A/zh active Pending
- 2016-01-27 CA CA2975078A patent/CA2975078A1/en active Pending
-
2019
- 2019-10-29 US US16/666,734 patent/US11591394B2/en active Active
-
2020
- 2020-07-28 JP JP2020127379A patent/JP7165701B2/ja active Active
-
2022
- 2022-02-11 AU AU2022200922A patent/AU2022200922A1/en not_active Withdrawn
-
2023
- 2023-01-30 US US18/161,163 patent/US12110328B2/en active Active
-
2024
- 2024-09-03 US US18/822,745 patent/US20240425592A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202091590A1 (ru) | Антитела против pd-l1 и варианты их применения | |
| RU2016129517A (ru) | Биспецифические антитела к her2 и способы применения | |
| CO2018013500A2 (es) | Anticuerpos anti-pd-l1 y usos de los mismos | |
| BR112019008010A2 (pt) | anticorpo monoclonal isolado ou fragmento imunologicamente ativo do mesmo, anticorpo monoclonal biespecífico isolado, composição farmacêutica, método para tratamento de uma doença em um sujeito humano em necessidade do mesmo, proteína de fusão, epítopo imunodominante codificado pelo gene cd47, e, molécula biológica | |
| MX2019008758A (es) | Anticuerpos anti-cd37 y usos de los mismos. | |
| WO2012149365A3 (en) | Antibodies selective for pathological tau dimers and oligomers and their uses in treatment, diagnosis, monitoring of tauopathies | |
| CO2018005932A2 (es) | Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas | |
| JP2013502204A5 (cg-RX-API-DMAC10.html) | ||
| JP2013538796A5 (cg-RX-API-DMAC10.html) | ||
| FI3389699T3 (fi) | Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja | |
| CY1121249T1 (el) | Αντισωμα εναντι του ειδικου προστατικου αντιγονου βλαστικου κυτταρου και χρησεις αυτου | |
| KR20190016966A (ko) | 길항성 항-종양 괴사 인자 수용체 슈퍼패밀리 항체 | |
| JP2018527919A5 (cg-RX-API-DMAC10.html) | ||
| UA105009C2 (uk) | Композиції та способи, призначені для спрямованого впливу антитіл на білок с5 системи комплементу | |
| BR112017019785A2 (pt) | anticorpos terapêuticos e seus usos | |
| PH12020550598A1 (en) | Methods and compositions for dosing of allogeneic chimeric antigen receptor t cells | |
| EA201591131A1 (ru) | Днк-конструкции антитела и способ их применения | |
| HRP20161656T4 (hr) | Sredstva za vezanje na cd33 | |
| RU2014101707A (ru) | АНТИ-Axl АНТИТЕЛА И ИХ ПРИМЕНЕНИЕ | |
| MX2014008963A (es) | Moleculas de anticuerpos biespecificos con celulas t transfectadas por antigeno y su uso en medicina. | |
| RU2017107773A (ru) | Антитела, специфичные к ммр9 | |
| CY1115349T1 (el) | Εξανθρωπισμενα αντι cxcr4 αντισωματα για τη θεραπεια καρκινου | |
| Naidoo et al. | Nanobodies enhancing cancer visualization, diagnosis and therapeutics | |
| RU2016143552A (ru) | Гуманизированные антитела к антигену Томсена-Фриденрайха | |
| RU2017111584A (ru) | Антитело против злокачественной клетки, противораковое лекарственное средство и способ тестирования злокачественного новообразования |